Sonnet bags ex-Serono neuropathy drug via Relief Therapeutics deal

Sonnet BioTherapeutics has struck a deal to acquire an ex-Serono drug from Relief Therapeutics. The agreement tees Sonnet up to advance the asset in chemotherapy-induced peripheral neuropathy using an equity facility worth up to $100 million.